SEC Filings

SAVARA INC filed this 424B3 on 20170315

Document Outline
Entire Document (5.2 MB)
Subdocument 1 - 424B3 - 424B3
  Page 1 - Filed Pursuant to Rule 424(b)(3)
  Page 2 - More information about Mast, Savara and the proposed transaction is contained in this proxy statemen
  Page 3 - MAST THERAPEUTICS, INC.
  Page 4 - vote of the holders of a majority of shares of Mast common stock having voting power outstanding on
  Page 5 - REFERENCES TO ADDITIONAL INFORMATION
  Page 6 - TABLE OF CONTENTS
  Page 7 - N/A
  Page 8 - N/A
  Page 9 - QUESTIONS AND ANSWERS ABOUT THE MERGER
  Page 10 - N/A
  Page 11 - N/A
  Page 12 - N/A
  Page 13 - N/A
  Page 14 - N/A
  Page 15 - N/A
  Page 16 - PROSPECTUS SUMMARY
  Page 17 - Opinion of the Mast Financial Advisor
  Page 18 - Treatment of Savara Options and Savara Restricted Shares
  Page 19 - Treatment of Savara Warrants
  Page 20 - Termination of the Merger Agreement
  Page 21 - Lock-Up Agreements
  Page 22 - Considerations with Respect to U.S. Federal Income Tax Consequences of the Merger
  Page 23 - Risk Factors
  Page 24 - Regulatory Approvals
  Page 25 - SELECTED HISTORICAL AND UNAUDITED PRO FORMA
  Page 26 - Condensed Consolidated Statements of Operations and Comprehensive Loss
  Page 27 - Selected Historical Consolidated Financial Data of Savara
  Page 28 - Selected Unaudited Pro Forma Condensed Combined Financial Data of Mast and Savara
  Page 29 - N/A
  Page 30 - Comparative Historical and Unaudited Pro Forma Per Share Data
  Page 31 - MARKET PRICE AND DIVIDEND INFORMATION
  Page 32 - RISK FACTORS
  Page 33 - If the conditions to the merger are not met, the merger may not occur.
  Page 34 - The market price of Mast common stock following the merger may decline as a result of the merger.
  Page 35 - Because the lack of a public market for Savara shares makes it difficult to evaluate the fairness of
  Page 36 - There is substantial doubt as to Mast s ability to continue as a going concern.
  Page 37 - Mast s product candidates are at intermediary to early stages of development, the success of Mast s
  Page 38 - N/A
  Page 39 - Mast will need to obtain additional funding to pursue its current business strategy and continue as
  Page 40 - If Mast is unable to consummate the merger with Savara or raise sufficient additional capital as nee
  Page 41 - Mast s ability to raise capital may be limited by applicable laws and regulations.
  Page 42 - Mast has significant goodwill and IPR D and impairment of goodwill and IPR D may have a significant
  Page 43 - Loss of personnel, through reductions in force or otherwise, could adversely impact Mast s ability t
  Page 44 - Mast expends substantial resources to comply with laws and regulations relating to public companies,
  Page 45 - Mast s employees, independent contractors and consultants, principal investigators, CROs, CMOs and o
  Page 46 - All ongoing and currently planned clinical studies of Mast s lead product candidate, AIR001, are inv
  Page 47 - N/A
  Page 48 - Clinical studies are very expensive, difficult to design and implement, often take many years to com
  Page 49 - N/A
  Page 50 - Mast does not have, and does not have plans to establish, any manufacturing facilities and are depen
  Page 51 - N/A
  Page 52 - Mast relies significantly on third parties to conduct its nonclinical testing and clinical studies a
  Page 53 - Mast may not achieve its projected development goals in the time frames Mast announces.
  Page 54 - Even if Mast receives regulatory approval for a product candidate, Mast may face development and reg
  Page 55 - Even if Mast receives regulatory approval to market one or more of its product candidates in the U.S
  Page 56 - N/A
  Page 57 - Mast s success depends in large part on its ability to prevent competitors from duplicating or devel
  Page 58 - Obtaining and maintaining Mast s patent protection depends on compliance with various procedural, do
  Page 59 - N/A
  Page 60 - Risks Related to Mast s Industry
  Page 61 - Mast faces potential product liability exposure and, if successful claims are brought against it, Ma
  Page 62 - Risks Related to Mast s Common Stock
  Page 63 - If Mast s common stock were delisted and determined to be a penny stock, a broker-dealer may find it
  Page 64 - Mast s stock price could decline significantly based on progress with and results of its clinical st
  Page 65 - Sales of substantial amounts of Mast s common stock or the perception that such sales may occur coul
  Page 66 - If Mast were to issue shares of its common stock or preferred stock that are available for issuance,
  Page 67 - N/A
  Page 68 - Risks Related to Savara s Business Strategy and Operations
  Page 69 - If Savara fails to attract and retain senior management and key scientific personnel, it may be unab
  Page 70 - Savara does not have, and does not have plans to establish manufacturing facilities. Savara complete
  Page 71 - N/A
  Page 72 - Savara relies significantly on third parties to conduct its nonclinical testing and clinical studies
  Page 73 - Savara is the process of integrating the systems, people and contracts from the recent acquisition o
  Page 74 - Savara may not achieve its projected development goals in the time frames Savara has announced.
  Page 75 - Savara s employees, independent contractors and consultants, principal investigators, CROs, CMOs and
  Page 76 - Risks Related to Drug Development and Commercialization
  Page 77 - Delays in commencement and completion of clinical studies are common and have many causes. Delays in
  Page 78 - N/A
  Page 79 - Clinical studies are very expensive, difficult to design and implement, often take many years to com
  Page 80 - N/A
  Page 81 - Even if Savara receives regulatory approval for a product candidate, Savara may face regulatory diff
  Page 82 - If any of Savara s product candidates for which Savara receive regulatory approval fails to achieve
  Page 83 - Savara must comply with the U.S. Foreign Corrupt Practices Act and similar foreign anti-corruption l
  Page 84 - N/A
  Page 85 - Savara s success depends on its ability to prevent competitors from duplicating or developing and co
  Page 86 - Obtaining and maintaining patent protection depends on compliance with various procedural, document
  Page 87 - Risks Related to Savara s Industry
  Page 88 - Savara is subject to uncertainty relating to healthcare reform measures and reimbursement policies t
  Page 89 - Savara faces potential product liability exposure and, if successful claims are brought against it,
  Page 90 - Risks Related to the Combined Organization
  Page 91 - The combined organization will incur costs and demands upon management as a result of complying with
  Page 92 - The combined company does not expect to pay any cash dividends in the foreseeable future.
  Page 93 - CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
  Page 94 - THE SPECIAL MEETING OF MAST STOCKHOLDERS
  Page 95 - Record Date and Voting Power
  Page 96 - Required Vote
  Page 97 - Solicitation of Proxies
  Page 98 - THE MERGER
  Page 99 - N/A
  Page 100 - N/A
  Page 101 - N/A
  Page 102 - N/A
  Page 103 - N/A
  Page 104 - N/A
  Page 105 - N/A
  Page 106 - N/A
  Page 107 - N/A
  Page 108 - Mast Reasons for the Merger
  Page 109 - N/A
  Page 110 - N/A
  Page 111 - Savara Reasons for the Merger
  Page 112 - Opinion of Roth Capital Partners as Mast s Financial Advisor
  Page 113 - The summary of Roth s opinion in this proxy statement is qualified in its entirety by reference to t
  Page 114 - N/A
  Page 115 - Consideration to be Paid in the Merger
  Page 116 - Estimated Mast Stand-Alone Valuation
  Page 117 - Discounted Cash Flow Analysis
  Page 118 - Mast Therapeutics, Inc.
  Page 119 - Private Valuation Step-up Analysis
  Page 120 - Public Comparable Analysis Respiratory
  Page 121 - Respiratory Licensing Comparables
  Page 122 - Discounted Cash Flow Analysis
  Page 123 - Savara Inc.
  Page 124 - Savara Inc.
  Page 125 - Information Regarding Financial Projections Used for Fairness Opinion Analysis
  Page 126 - Potential Benefits upon Change in Control of Mast
  Page 127 - Cash and Restricted Stock Unit Awards
  Page 128 - Restricted Stock Units Awards
  Page 129 - Acceleration of Director Equity Awards
  Page 130 - Interests of Certain Savara Directors, Executive Officers and Affiliates in the Merger
  Page 131 - Stock Options and Warrants.
  Page 132 - Management Following the Merger
  Page 133 - Stock Options, Restricted Stock and Warrants
  Page 134 - Merger Consideration
  Page 135 - Effective Time of the Merger
  Page 136 - N/A
  Page 137 - STOCKHOLDERS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL I
  Page 138 - Information Reporting and Backup Withholding
  Page 139 - THE PRECEDING DISCUSSION DOES NOT PURPORT TO BE A COMPLETE ANALYSIS OR DISCUSSION OF ALL OF THE MERG
  Page 140 - N/A
  Page 141 - Weinberger
  Page 142 - Weinberger
  Page 143 - THE MERGER AGREEMENT
  Page 144 - Exchange Ratio
  Page 145 - Determination of Net Cash
  Page 146 - minus
  Page 147 - Treatment of Savara Options and Savara Restricted Shares
  Page 148 - Amendments to the Amended and Restated Certificate of Incorporation of Mast
  Page 149 - N/A
  Page 150 - N/A
  Page 151 - Representations and Warranties
  Page 152 - No Solicitation
  Page 153 - N/A
  Page 154 - Meetings of Stockholders
  Page 155 - Covenants; Conduct of Business Pending the Merger
  Page 156 - N/A
  Page 157 - N/A
  Page 158 - Regulatory Approvals
  Page 159 - Financing
  Page 160 - Other Agreements
  Page 161 - N/A
  Page 162 - Termination of the Merger Agreement
  Page 163 - N/A
  Page 164 - Termination Fee
  Page 165 - Fee payable by Savara
  Page 166 - AGREEMENTS RELATED TO THE MERGER
  Page 167 - N/A
  Page 168 - MATTERS BEING SUBMITTED TO A VOTE OF MAST STOCKHOLDERS
  Page 169 - Mast Proposal No. 2: Approval of the Amendment and Restatement of the Amended and Restated Certifica
  Page 170 - Potential Increased Investor Interest
  Page 171 - Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates
  Page 172 - Potential Anti-Takeover Effect
  Page 173 - INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCO
  Page 174 - Information Reporting and Backup Withholding
  Page 175 - Mast Proposal No. 4: Advisory Non-Binding Vote on Merger-Related Executive Compensation Arrangements
  Page 176 - Mast Proposal No. 5: Approval of Possible Adjournment of the Mast Special Meeting
  Page 177 - MAST BUSINESS
  Page 178 - Rationale for Development of AIR001 in HFpEF
  Page 179 - Journal of Clinical Investigation
  Page 180 - Phase 2 INABLE-TRAINING Study
  Page 181 - Future Development in HFpEF
  Page 182 - Intellectual Property
  Page 183 - Competition
  Page 184 - N/A
  Page 185 - N/A
  Page 186 - N/A
  Page 187 - Expedited Review Programs
  Page 188 - N/A
  Page 189 - Other Healthcare Laws and Compliance Requirements
  Page 190 - Government Regulation Outside the U.S.
  Page 191 - SAVARA BUSINESS
  Page 192 - Savara s product candidate pipeline
  Page 193 - Change from baseline in FEV1 (left) and Time to use of other antibiotic for respiratory infection (r
  Page 194 - Strategy
  Page 195 - Current MRSA treatment options in CF
  Page 196 - AeroVanc Product Description
  Page 197 - Completed Clinical Studies
  Page 198 - Phase 2
  Page 199 - Vancomycin sputum concentrations after administration of AeroVanc at various time points
  Page 200 - Change from baseline in FEV1
  Page 201 - Change in MRSA density in sputum
  Page 202 - Time to use of other antibiotics for respiratory infection
  Page 203 - Current treatment options of PAP
  Page 204 - Molgradex Product Description
  Page 205 - Completed Clinical Studies
  Page 206 - Mean WBC Over Time and After Multiple Ascending Doses
  Page 207 - Molgradex Pharmacology Studies
  Page 208 - GM-CSF receptor function by Molgradex or control recombinant human GM-CSF
  Page 209 - Manufacturing and Supply
  Page 210 - Molgradex Manufacturing
  Page 211 - PARI Pharma GmbH
  Page 212 - Government Regulation
  Page 213 - in vitro
  Page 214 - NDA Submission and Review by the FDA
  Page 215 - N/A
  Page 216 - Orphan Drug Status
  Page 217 - Post-Approval Requirements
  Page 218 - Government Regulation of Combination Products
  Page 219 - N/A
  Page 220 - N/A
  Page 221 - Coverage and Reimbursement
  Page 222 - Foreign Regulation
  Page 223 - Trade Secrets
  Page 224 - in vitro
  Page 225 - Employees
  Page 226 - MAST MANAGEMENT S DISCUSSION AND ANALYSIS OF
  Page 227 - Critical Accounting Policies and Significant Judgments and Estimates
  Page 228 - Business Combinations
  Page 229 - Goodwill for Impairment
  Page 230 - Results of Operations Overview
  Page 231 - Selling, General and Administrative Expenses.
  Page 232 - Other (Expense)/Income, Net.
  Page 233 - Selling, General and Administrative Expenses
  Page 234 - Operating Expenses
  Page 235 - Transaction-Related Expenses.
  Page 236 - Liquidity and Capital Resources
  Page 237 - N/A
  Page 238 - N/A
  Page 239 - Operating activities
  Page 240 - Recent Accounting Pronouncements
  Page 241 - QUANTITATIVE AND QUALITATIVE DISCLOSURES
  Page 242 - SAVARA MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
  Page 243 - Recent Events
  Page 244 - General and Administrative Expenses
  Page 245 - Fair Value of Common Stock
  Page 246 - Results of Operations Comparison of Years Ended December 31, 2016 and 2015
  Page 247 - Liquidity and Capital Resources
  Page 248 - Cash Flows
  Page 249 - Contractual Obligations and Other Commitments
  Page 250 - License and Royalty Agreements
  Page 251 - Off-Balance Sheet Arrangements
  Page 252 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT SAVARA MARKET RISK
  Page 253 - MANAGEMENT FOLLOWING THE MERGER
  Page 254 - David Lowrance
  Page 255 - Joseph S. McCracken
  Page 256 - Composition of the Board of Directors
  Page 257 - Compensation Committee
  Page 258 - Nominating and Governance Committee
  Page 259 - N/A
  Page 260 - 2016 Savara Director Compensation
  Page 261 - Executive Compensation
  Page 262 - Non-Equity Incentive Plan
  Page 263 - Employment and Severance Agreements
  Page 264 - Employment Benefits Plans
  Page 265 - Mast s 2015 Omnibus Incentive Plan
  Page 266 - Eligibility; Awards to Certain Individuals and Groups.
  Page 267 - Stock Options.
  Page 268 - Restricted Stock Awards.
  Page 269 - N/A
  Page 270 - Adjustments to Awards Subject to Performance Criteria.
  Page 271 - Nontransferability of Awards.
  Page 272 - Termination of Employment.
  Page 273 - CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF SAVARA
  Page 274 - Series B Preferred Stock Warrants
  Page 275 - UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
  Page 276 - N/A
  Page 277 - Unaudited Pro Forma Condensed Combined Balance Sheet
  Page 278 - Unaudited Pro Forma Condensed Combined Statement of Operations
  Page 279 - NOTES TO THE UNAUDITED PRO FORMA CONDENSED
  Page 280 - 3. Pro Forma Adjustments
  Page 281 - N/A
  Page 282 - 4. Serendex s Historical Financial Statements
  Page 283 - Translation of Serendex s Historical Financial Statements to US Dollars
  Page 284 - DESCRIPTION OF MAST CAPITAL STOCK
  Page 285 - Anti-Takeover Effects of Provisions of Mast s Charter Documents and Delaware Law
  Page 286 - No Cumulative Voting
  Page 287 - N/A
  Page 288 - COMPARISON OF RIGHTS OF HOLDERS OF MAST STOCK AND SAVARA STOCK
  Page 289 - N/A
  Page 290 - N/A
  Page 291 - N/A
  Page 292 - N/A
  Page 293 - N/A
  Page 294 - PRINCIPAL STOCKHOLDERS OF MAST
  Page 295 - N/A
  Page 296 - N/A
  Page 297 - PRINCIPAL STOCKHOLDERS OF SAVARA
  Page 298 - N/A
  Page 299 - LEGAL MATTERS
  Page 300 - TRADEMARK NOTICE
  Page 301 - INDEX TO FINANCIAL STATEMENTS
  Page 302 - Report of Independent Registered Public Accounting Firm
  Page 303 - Report of Independent Registered Public Accounting Firm
  Page 304 - Report of Independent Registered Public Accounting Firm
  Page 305 - Mast Therapeutics, Inc. and Subsidiaries
  Page 306 - Mast Therapeutics, Inc. and Subsidiaries
  Page 307 - Mast Therapeutics, Inc. and Subsidiaries
  Page 308 - Mast Therapeutics, Inc. and Subsidiaries
  Page 309 - Mast Therapeutics, Inc. and Subsidiaries
  Page 310 - Liquidity as of December 31, 2015
  Page 311 - Business Combinations
  Page 312 - Property and Equipment
  Page 313 - Concentration of Credit Risk and Significant Sources of Supply
  Page 314 - Research and Development Expense
  Page 315 - Comprehensive Income/(Loss)
  Page 316 - Leases (ASC 842)
  Page 317 - Acquired In-Process Research and Development
  Page 318 - Deferred Income Tax Liability
  Page 319 - N/A
  Page 320 - N/A
  Page 321 - Hercules Loan and Security Agreement
  Page 322 - Summary of Carrying Value
  Page 323 - Underwritten Public Offering of Common Stock and Warrants
  Page 324 - Warrant Exercises
  Page 325 - 2015 Omnibus Incentive Plan
  Page 326 - Summary of 2016 Stock Option Activity
  Page 327 - Compensation Stock Compensation
  Page 328 - N/A
  Page 329 - N/A
  Page 330 - N/A
  Page 331 - Quarterly statements of operations data
  Page 332 - Fifth Amendment to Loan Agreement and Third Amendment to Warrant Agreement with Hercules
  Page 333 - Anticipated Severance Expense
  Page 334 - Report of Independent Auditors
  Page 335 - Savara Inc. and Subsidiary
  Page 336 - Savara Inc. and Subsidiary
  Page 337 - Savara Inc. and Subsidiary
  Page 338 - Savara Inc. and Subsidiary
  Page 339 - Savara Inc. and Subsidiary
  Page 340 - Principles of Consolidation
  Page 341 - Concentration of Credit Risk
  Page 342 - Property and Equipment
  Page 343 - Segment Reporting
  Page 344 - Stock-Based Compensation
  Page 345 - N/A
  Page 346 - 3. Property and Equipment, Net
  Page 347 - Voluntary Conversion
  Page 348 - Accounting for 2014 Notes
  Page 349 - Voluntary Conversion
  Page 350 - IPO Conversion
  Page 351 - 5. Litigation
  Page 352 - 7. Acquisition of Serendex Pharmaceuticals
  Page 353 - Pro Forma Financial Information
  Page 354 - 9. Fair Value Measurements
  Page 355 - N/A
  Page 356 - 10. Redeemable Convertible Preferred Stock
  Page 357 - Liquidation
  Page 358 - Dividend and Voting Rights
  Page 359 - Stock Options
  Page 360 - Restricted Stock
  Page 361 - 13. Income Taxes
  Page 362 - N/A
  Page 363 - 14. Net Loss per Share
  Page 364 - Modification of the 2016 Notes
  Page 365 - INDEPENDENT AUDITOR S REPORT
  Page 366 - Consolidated Income Statement
  Page 367 - Consolidated Balance Sheet
  Page 368 - Consolidated Changes in equity
  Page 369 - Consolidated Cash Flow Statement
  Page 370 - Notes
  Page 371 - 3. SEGMENT DATA
  Page 372 - Assumptions for warrants granted in 2015
  Page 373 - 6. FEE TO STATUTORY AUDITORS
  Page 374 - 10. ALLOCATION OF LOSS
  Page 375 - 13. DEPOSITS
  Page 376 - 16. LOANS FROM SHAREHOLDERS
  Page 377 - 21. STATEMENT OF CASH FLOWS ADJUSTMENTS
  Page 378 - Commercial risks
  Page 379 - Capital resources
  Page 380 - 25. BOARD OF DIRECTORS AND EXECUTIVE MANAGEMENT
  Page 381 - EXECUTIVE MANAGEMENT
  Page 382 - Basis of consolidation
  Page 383 - Cost of goods sold
  Page 384 - BALANCE SHEET ITEMS
  Page 385 - Write-down of assets
  Page 386 - Other receivables, prepayments and accrued expenses
  Page 387 - Unaudited Consolidated Income Statement
  Page 388 - Unaudited Consolidated Balance Sheet
  Page 389 - Unaudited Consolidated Changes in equity
  Page 390 - Unaudited Consolidated Cash Flow Statement
  Page 391 - Unaudited Notes
  Page 392 - Development costs
  Page 393 - 4. OTHER EXPENSES AND COSTS BY FUNCTION
  Page 394 - 7. TAX RECEIVABLES AND DEFERRED TAX
  Page 395 - 10. STATEMENT OF CASH FLOWS ADJUSTMENTS
  Page 396 - New standards and interpretations
  Page 397 - Translation of foreign currency
  Page 398 - Staff expenses
  Page 399 - Tangible assets
  Page 400 - Deferred tax
  Page 401 - Cash flow from capitalised activities
  Page 402 - Annex A
  Page 403 - N/A
  Page 404 - N/A
  Page 405 - Exhibits
  Page 406 - AGREEMENT AND PLAN OF MERGER AND REORGANIZATION
  Page 407 - Parent
  Page 408 - 1.4 Certificate of Incorporation; Bylaws; Reverse Split; Parent Name Change.
  Page 409 - (d)
  Page 410 - 1.7 Dissenting Shares
  Page 411 - (c)
  Page 412 - 1.10 Calculation of Net Cash.
  Page 413 - 1.11 No Further Rights
  Page 414 - (c)
  Page 415 - 2.3 Authority; Non-Contravention; Approvals
  Page 416 - SEC
  Page 417 - Liability
  Page 418 - (e)
  Page 419 - 2.8 Intellectual Property
  Page 420 - (f)
  Page 421 - (c)
  Page 422 - (g)
  Page 423 - ERISA
  Page 424 - (d)
  Page 425 - (h)
  Page 426 - (b)
  Page 427 - 2.16 Company Contracts.
  Page 428 - (xi)
  Page 429 - (b)
  Page 430 - (b)
  Page 431 - 3.3 Authority; Non-Contravention; Approvals.
  Page 432 - 3.4 Anti-Takeover Statutes Not Applicable
  Page 433 - (f)
  Page 434 - (c)
  Page 435 - (b)
  Page 436 - (c)
  Page 437 - (b)
  Page 438 - (d)
  Page 439 - (h)
  Page 440 - (i)
  Page 441 - (xiii)
  Page 442 - 3.17 Disclosure
  Page 443 - (b)
  Page 444 - (k)
  Page 445 - (f)
  Page 446 - (o)
  Page 447 - (c)
  Page 448 - (b)
  Page 449 - Parent Stockholder Approval Matters
  Page 450 - provided
  Page 451 - Confidentiality Agreement
  Page 452 - 5.7 Notification of Certain Matters
  Page 453 - 5.11 Board of Directors and Officers of Parent
  Page 454 - (b)
  Page 455 - Acceptable Parent Confidentiality Agreement
  Page 456 - 5.17 Company Options; Restricted Shares
  Page 457 - (d)
  Page 458 - 5.22 Company and Parent Disclosure Schedules
  Page 459 - (b)
  Page 460 - ARTICLE 6
  Page 461 - (c)
  Page 462 - (d)
  Page 463 - (f)
  Page 464 - (ii)
  Page 465 - (f)
  Page 466 - (b)
  Page 467 - 8.5 Entire Agreement.
  Page 468 - (c)
  Page 469 - knowledge of Parent
  Page 470 - IN WITNESS WHEREOF
  Page 471 - EXHIBIT A
  Page 472 - Company Disclosure Schedule
  Page 473 - Consent
  Page 474 - provided
  Page 475 - FDA
  Page 476 - Legal Proceeding
  Page 477 - Parent Capital Stock
  Page 478 - Parent Unaudited Interim Balance Sheet
  Page 479 - Proxy Statement/Prospectus/ Information Statement
  Page 480 - provided
  Page 481 - N/A
  Page 482 - N/A
  Page 483 - Exhibit A Lock-Up Agreement Signatories
  Page 484 - Annex B
  Page 485 - N/A
  Page 486 - N/A
  Page 487 - Annex C
  Page 488 - N/A
  Page 489 - N/A
  Page 490 - N/A
  Page 491 - Annex D
  Page 492 - ARTICLE V